English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, we investigated the potential association between the severity of COVID-19 (coronavirus disease 2019) and nasopharyngeal viral loads or serum antibody levels and evaluate the temporal dynamics of antibodies against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Using ELISA (enzyme-linked immunosorbent assay), we determined the presence of IgA, IgM and IgG antibodies in 450 serum samples from 122 patients for a period of 9 months after disease onset. Viral burden was quantified by RT-PCR (reverse transcription polymerase chain reaction) in 270 nasopharyngeal swab samples from 122 patients for a period of 4 weeks after the onset of the symptoms. Higher antibody values were generally seen in patients with moderate and severe disease compared to patients with mild COVID-19. Significant differences were established in IgA and IgG antibody levels at weeks 3–4 and 5–13 after the disease onset. In all severity groups, seroconversion rates were high and a similar pattern was observed with IgM antibodies quickly decreasing after reaching peak levels and IgA and IgG antibodies persisting at high values up to 9 months. The mean viral loads were higher in the mild group during the first 2 weeks and in the moderate and severe groups later on. However, the differences were not statistically significant. The IgA and IgG antibody response was significantly stronger in patients with moderate/severe disease around the time of peak antibody production as well as in vaccinated patients. No definitive association between viral load levels and the severity of COVID-19 was observed.

Antibody dynamics and viral load in COVID-19: differences in mild, moderate and severe cases